Rapport Therapeutics, Inc. (RAPP) Stock Price & Analysis
Rapport Therapeutics, Inc. (RAPP) fell 2.29% to USD 35.84 as of June 10, 2026 at 01:54 UTC, according to Nexqual real-time market data.
RAPP last closed at USD 36.68; the session ranged USD 34.55–38.46 on volume of 256,709 shares. Market capitalization is $1.71B, with a 52-week range of USD 10.51–42.27 (NGM). Source: Nexqual, June 10, 2026 at 01:54 UTC.
Key Statistics (as of June 10, 2026 at 01:54 UTC)
| Price | USD 35.84 |
|---|---|
| Change | ▼ 2.29% (down) |
| Previous Close | USD 36.68 |
| Open | USD 37.31 |
| Day Range | USD 34.55 – 38.46 |
| 52-Week Range | USD 10.51 – 42.27 |
| Volume | 256,709 shares |
| Market Cap | $1.71B |
| Exchange | NGM |
Technical Analysis (RAPP)
Nexqual's technical model rates RAPP "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 01:54 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 45.76 (neutral) |
| vs SMA50 | Below (USD 36) |
| MACD | 0.2 (positive) |
Analyst Ratings (RAPP)
Wall Street analysts rate RAPP "Strong Buy" based on 10 analysts, with a mean price target of USD 57.1 (range USD 40–80), per Nexqual as of June 10, 2026 at 01:54 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 57.1 |
| High Target | USD 80 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (RAPP)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -1 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.42 vs est -0.71 ▲ beat |
| 2025-12-31 | USD -0.72 vs est -0.67 ▼ miss |
| 2025-09-30 | USD -0.71 vs est -0.73 ▲ beat |
| 2025-06-30 | USD -0.75 vs est -0.77 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Financials & Fundamentals (RAPP)
| Total Revenue | $20.00M |
|---|---|
| Gross Margin | +34.28% |
| Operating Margin | -121.08% |
| Profit Margin | +0.00% |
| ROE | -28.33% |
| Debt / Equity | 2.29 |
| Current Ratio | 27.08 |
| Total Cash | $476.78M |
| Total Debt | $10.80M |
| Free Cash Flow | $-49.43M |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Financial Health Score (RAPP)
Nexqual rates Rapport Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:54 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $477M cash vs $11M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$80M |
| Efficiency | Critical — ROE -28%, ROA -19.1% |
Ownership (RAPP)
| Insider Ownership | +4.65% |
|---|---|
| Institutional Ownership | +109.48% |
| Shares Outstanding | 47.83M |
| Float | 31.75M |
| Short % of Float | +8.15% |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Leadership (RAPP)
Rapport Therapeutics, Inc. is led by Abraham N. Ceesay (age 47), CEO, President, Treasurer & Director, per Nexqual as of June 10, 2026 at 01:54 UTC.
| CEO, President, Treasurer & Director | Abraham N. Ceesay (age 47) |
|---|---|
| Founder & Independent Chairman | Steven M. Paul (age 74) |
| Chief Financial Officer | Troy A. Ignelzi (age 57) |
| Founder & Chief Scientific Officer | David Bredt (age 59) |
| Chief Operating Officer | Cheryl Gault (age 45) |
Major Backers & Investors (RAPP)
Notable institutional backers of Rapport Therapeutics, Inc. include FMR, LLC, Trv Gp V, LLC , Fidelity, according to Nexqual as of June 10, 2026 at 01:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.99% |
| Trv Gp V, LLC | 14.92% |
| Fidelity | 8.22% |
| Arch Venture Management, Llc | 7.8% |
| SmallCap World Fund Inc | 7.6% |
| Capital International Investors | 6.48% |
| Cormorant Asset Management, LP | 6.18% |
| Goldman Sachs | 6.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.7% |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
From Rapport Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
- The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
- It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBX | MBX Biosciences, Inc. | USD 29.87 | ▼ 1.35% |
| MLYS | Mineralys Therapeutics, Inc. | USD 24.18 | ▲ 2.07% |
| BCAX | Bicara Therapeutics Inc. | USD 20.56 | ▲ 2.8% |
| ALMS | Alumis Inc. | USD 20.01 | ▲ 4.98% |
| AVBP | ArriVent BioPharma, Inc. | USD 30.55 | ▲ 0.66% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:54 UTC. This page is informational and not investment advice.